It's the 2nd case in a month that the fda briefing versus the fda's tone at the meeting were very different. In Xatelto's case (for ACS) things went the other way around i.e. positive review and negative panel.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.